US 12,239,126 B2
Methods and compositions for preserving tissues and organs
Martin L. Yarmush, Newton, MA (US); Mehmet Toner, Wellesley, MA (US); Maria-Louisa Izamis, Boston, MA (US); Timothy Antonie Berendsen, Melrose, MA (US); Robert Marius Bieganski, Cambridge, MA (US); Osman Berk Usta, Watertown, MA (US); Basak Elif Uygun, Newton, MA (US); Mustafa Korkut Uygun, Newton, MA (US); and Sinem Perk, Chicago, IL (US)
Assigned to The General Hospital Corporation, Boston, MA (US)
Filed by THE GENERAL HOSPITAL CORPORATION, Boston, MA (US)
Filed on Dec. 6, 2019, as Appl. No. 16/705,966.
Application 16/705,966 is a division of application No. 13/695,459, granted, now 10,575,515, previously published as PCT/US2011/035223, filed on May 4, 2011.
Claims priority of provisional application 61/447,905, filed on Mar. 1, 2011.
Claims priority of provisional application 61/364,186, filed on Jul. 14, 2010.
Claims priority of provisional application 61/330,959, filed on May 4, 2010.
Prior Publication US 2020/0236924 A1, Jul. 30, 2020
Int. Cl. A01N 1/02 (2006.01); G01N 33/50 (2006.01); G01N 1/42 (2006.01)
CPC A01N 1/0226 (2013.01) [G01N 33/5091 (2013.01); G01N 1/42 (2013.01)] 10 Claims
OG exemplary drawing
 
1. A method for extending the viable preservation of a harvested organ for transplantation, the method comprising:
contacting at least a portion of the harvested organ with a preservation perfusion solution, wherein the preservation perfusion solution comprises (i) at least 3 of the following: insulin, L-glutamine, hydrocortisone, heparin, penicillin, streptomycin sulfate, and adenosine, and (ii) a PPARγ ligand selected from the group consisting of troglitazone and rosiglitazone, or derivatives thereof,
wherein the harvested organ is a liver, pancreas, kidney, spleen, or lung.